Efficacy and safety of treatment of moderate and severe psoriasis with the interleukin 23 inhibitor risankizumab

A review of the literature on the use of the genetically engineered biological drug Skyrizi (INN: risankizumab) for the treatment of psoriasis in patients is presented. The problem of high dissatisfaction of patients with the available means (methods) of therapy for this dermatosis is discussed. Inhibition of regulatory IL-23 seems to be a very promising direction of therapy, which makes it possible to block the immunopathogenesis of the disease. The IL-23 inhibitor risankizumab is a highly effective GEBA for the treatment of moderate to severe psoriasis in patients. The use of this drug is accompanied by a very rapid and stable therapeutic response in the form of clear or almost clear skin. Long-term use of risankizumab demonstrates the maintenance of a stable therapeutic response without a tendency to decrease. Risankizumab has a favorable safety profile with a low risk of infections and malignancies. At the same time, such adverse events as the development of tuberculosis or inflammatory bowel disease are not typical for therapy with these GIBDs.